Showing 1 - 20 results of 61 for search '"респираторно-синцитиальный вирус"', query time: 0.72s Refine Results
  1. 1
    Academic Journal

    Source: Medical science of Uzbekistan; No. 3 (2025): May-June; 103-106 ; Медицинская наука Узбекистана; № 3 (2025): Май-Июнь; 103-106 ; O`zbekiston tibbiyot ilmi; No. 3 (2025): May-Iyun; 103-106 ; 2181-3612

    File Description: application/pdf

  2. 2
    Academic Journal

    Contributors: The study was supported by the Russian Science Foundation grant No. 23‐24‐00492, Исследование выполнено при поддержке гранта РНФ № 23‐24‐00492

    Source: South of Russia: ecology, development; Том 18, № 4 (2023); 173-181 ; Юг России: экология, развитие; Том 18, № 4 (2023); 173-181 ; 2413-0958 ; 1992-1098

    File Description: application/pdf

    Relation: https://ecodag.elpub.ru/ugro/article/view/3010/1393; Simmonds P., Gorbalenya A.E., Harvala H., Hovi T., Knowles N.J., Lindberg A.M., Oberste M.S., Palmenberg A.C., Reuter G., Skern T., Tapparel C., Wolthers K.C., Woo P.C.Y., Zell R. Recommendations for the nomenclature of enteroviruses and rhinoviruses // Archives of Virology. 2020. N 165. C. 793–797. doi:10.1007/s00705-019-04520-6; Royston L., Tapparel C. Rhinoviruses and respiratory enteroviruses: not as simple as ABC // Viruses. 2016. N 8. P. 151–156. doi:10.3390/v8010016; Fine J., Bray‐Aschenbrenner A., Williams H, Buchanan P., Werner J. The Resource Burden of Infections with Rhinovirus/Enterovirus, Influenza, and Respiratory Syncytial Virus in Children // Clin. Pediatr. 2018. N 58. C. 177–184.; Marjomäki V., Kalander K., Hellman M., Permi P. Enteroviruses and coronaviruses: similarities and therapeutict argets // Expert Opinion on Therapeutic Targets. 2021. V. 11. N 1. P. 23–27. doi:10.1080/14728222.2021.1952985; Tapparel C., Siegrist F., Petty T.J., Kaiser L. Picornavirus and enterovirus diversity with associated human diseases // Infection, Genetics and Evolution. 2013. N 14. P. 282–293. doi:10.1016/j.meegid.2012.10.016; Hayes A., Nguyen D., Andersson M., et al. A European multicentre evaluation of detection and typing methods for human enteroviruses and parechoviruses using RNA transcripts. Journal of Medical Virology. 2020. V. 92. P. 1065–1074. doi:10.1002/jmv.25659; Harvala H., Jasir A., Penttinen P., et al. Surveillance and laboratory detection for non‐polio enteroviruses in the European Union/European Economic Area, 2016 // Euro Surveill. 2017. V. 22. P. 233–236. doi:10.2807/1560-7917.ES.2017.22.45.16-00807; Holm‐Hansen C.C., Midgley S.E., Fischer T.K. Global emergence of enterovirus D68 : a systematic review // The Lancet Infectious Diseases. 2016. V. 16. N 5. P. 64–75. doi:10.1016/S1473-3099(15)00543-5; Poelman R., Schuffenecker I., Van Leer‐Buter C., Josset L., Niesters H.G., Lina B. European surveillance for enterovirus D68 during the emerging North‐American outbreak in 2014 // Journal of Clinical Virology. 2015. V. 71. P. 1–9. doi:10.1016/j.jcv.2015.07.296; Harvala H., Broberg E., Benschop K., Berginc N., Ladhani Sh., Susi P., Christiansen Claus., McKenna J., Allen D., Makiello Ph., McAllister G., Carmen M., Zakikhany K., Dyrdak R., Nielsen Xiaohui, Madsen T., Paul J., Moore C., Karin von Eije, Piralla A., Fischer Thea K. Recommendations for enterovirus diagnostics and characterisation within and beyond Europe // Journal of Clinical Virology. 2018. V. 101. P. 11–17. doi:10.1016/j.jcv.2018.01.008; Fillatre A., François C., Segard C., et al. Epidemiology and seasonality of acute respiratory infections in hospitalized children over four consecutive years (2012– 2016) // Journal of Clinical Virology. 2018. T. 102. C. 27–31. doi:10.1016/j.jcv.2018.02.010; Kurskaya O., Ryabichenko T., Leonova N., Shi W., Bi H., Sharshov K., Kazachkova E., Sobolev I., Prokopyeva E., Kartseva T., et al. Viral etiology of Acute Respiratory Infections in Hospitalized Children in Novosibirsk City, Russia (2013–2017) // PLoS ONE. 2018. V. 13. N 9. doi:10.1371/journal.pone.0200117; Kurskaya O.G., Prokopyeva E.A., Sobolev I.A., Solomatina M.V., Saroyan T.A., Dubovitskiy N.A., Derko A.A., Nokhova A.R., Anoshina A.V., Leonova N.V., et al. Changes in the Etiology of Acute Respiratory Infections among Children in Novosibirsk, Russia, between 2019 and 2022: The Impact of the SARS‐CoV‐2 Virus // Viruses. 2023. V. 15. P. 4. doi:10.3390/v15040934; Baertl S., Pietsch C., Maier M., Hönemann M., Bergs S., Liebert U.G. Enteroviruses in Respiratory Samples from Paediatric Patients of a Tertiary Care Hospital in Germany // Viruses. 2021. V. 13. P. 5. doi:10.3390/v13050882; Poelman R., Schölvinck E.H., Borger R., Niesters H.G., Van Leer‐Buter C. The emergence of enterovirus D68 in a Dutch University Medical Center and the necessity for routinely screening for respiratory viruses // Journal of Clinical Virology. 2015. V. 62. P. 1–5.; Andrés C., Vila J., Gimferrer L., Piñana M., Esperalba J., Codina M.G., Barnés M., Martín M.C., Fuentes F., Rubio S., et al. Surveillance of enteroviruses from paediatric patients attended at a tertiary hospital in Catalonia from 2014 to 2017 // Journal of Clinical Virology. 2019. V. 110. P. 29–35.; Kiseleva I., Grigorieva E., Larionova N., Al Farroukh M, Rudenko L. COVID‐19 in Light of Seasonal Respiratory Infections // Biology. 2020. N 9. 240. DOI:10.3390/biology9090240; Kiseleva I., Ksenafontov A. COVID‐19 Shuts Doors to Flu but Keeps Them Open to Rhinoviruses // Biology. 2021. V. 10. P. 8. doi:10.3390/biology10080733; Cai X., Wang Q., Lin G., et al. Respiratory virus infections among children in South China // Journal of Medical Virology. 2014. V. 86. P. 1249–1255.; Tabatabai J., Ihling C.M., Manuel B., Rehbein R.M., Schnee S.V., Hoos J., Pfeil J., Grulich‐Henn J., Schnitzler P. Viral Etiology and Clinical Characteristics of Acute Respiratory Tract Infections in Hospitalized Children in Southern Germany (2014–2018) // Open Forum Infectious Diseases. 2023. V. 10. N 3. DOI:10.1093/ofid/ofad110; Fine J., Bray‐Aschenbrenner A., Williams H., Buchanan P., Werner J. The Resource Burden of Infections With Rhinovirus/Enterovirus, Influenza, and Respiratory Syncytial Virus in Children // Clinical Pediatrics (Phila). 2019. V. 58. Ed. 2. P. 177–184. DOI:10.1177/0009922818809483.; https://ecodag.elpub.ru/ugro/article/view/3010

  3. 3
    Academic Journal

    Contributors: This study was conducted by the Scientific Centre for Expert Evaluation of Medicinal Products as part of the applied research funded under State Assignment No. 056-00026-24-01 (R&D Registry No. 124022200103-5), Работа выполнена в рамках государственного задания ФГБУ «НЦЭСМП» Минздрава России № 056-00026-24-01 на проведение прикладных научных исследований (номер государственного учета НИР 124022200103-5)

    Source: Biological Products. Prevention, Diagnosis, Treatment; Том 24, № 3 (2024); 255-269 ; БИОпрепараты. Профилактика, диагностика, лечение; Том 24, № 3 (2024); 255-269 ; 2619-1156 ; 2221-996X ; 10.30895/2221-996X-2024-24-3

    File Description: application/pdf

    Relation: https://www.biopreparations.ru/jour/article/view/592/912; https://www.biopreparations.ru/jour/article/downloadSuppFile/592/1015; Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and highrisk adults. N Engl J Med. 2005;352(17):1749–59. https://doi.org/10.1056/nejmoa043951; The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3):531–7. PMID: 9738173; Reicherz F, Abu-Raya B, Akinseye O, Rassekh SR, Wiens MO, Lavoie PM. Efficacy of palivizumab immunoprophylaxis for reducing severe RSV outcomes in children with immunodeficiencies: a systematic review. J Pediatric Infect Dis Soc. 2024;13(2):136–43. https://doi.org/10.1093/jpids/piae004; Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med. 2023;388(7):595–608. https://doi.org/10.1056/nejmoa2209604; Walsh EE, Pérez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med. 2023;388(16):1465–77. https://doi.org/10.1056/nejmoa2213836; Melgar M, Britton A, Roper LE, Talbot HK, Long SS, Kot ton CN, Havers FP. Use of respiratory syncytial virus vaccines in older adults: recommendations of the advisory committee on immunization practices — United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(29):793–801. https://doi.org/10.15585/mmwr.mm7229a4; Acosta P, Caballero MT, Polack FP. Brief history and characterization of enhanced respiratory syncytial virus disease. Clin Vaccine Immunol. 2016;23(3):189–95. https://doi.org/10.1128/cvi.00609-15; Altamirano-Lagos MJ, Díaz FE, Mansilla MA, Rivera-Pérez D, Soto D, McGill JL, et al. Current animal models for understanding the pathology caused by the respiratory syncytial virus. Front Microbiol. 2019;10:873. https://doi.org/10.3389/fmicb.2019.00873; Walsh EE, Hall CB. Respiratory Syncytial Virus (RSV). Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 2015:1948–1960.e3. https://doi.org/10.1016/B978-1-4557-4801-3.00160-0; van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R, Fouchier RA, Osterhaus AD. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med. 2001;7(6):719–24. https://doi.org/10.1038/89098; Collins PL, Fearns R, Graham BS. Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. Curr Top Microbiol Immunol. 2013;372:3–38. https://doi.org/10.1007/978-3-642-38919-1_1; Tawar RG, Duquerroy S, Vonrhein C, Varela PF, DamierPiolle L, Castagne N, et al. Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus. Science. 2009;326(5957):1279–83. https://doi.org/10.1126/science.1177634; Yu JM, Fu YH, Peng XL, Zheng YP, He JS. Genetic diversity and molecular evolution of human respiratory syncytial virus A and B. Sci Rep. 2021;11(1):12941. https://doi.org/10.1038/s41598-021-92435-1; Tan L, Lemey P, Houspie L, Viveen MC, Jansen NJ, van Loon AM, et al. Genetic variability among complete human respiratory syncytial virus subgroup A genomes: bridging molecular evolutionary dynamics and epidemiology. PLoS One. 2012;7(12):e51439. https://doi.org/10.1371/journal.pone.0051439; Vos LM, Oosterheert JJ, Kuil SD, Viveen M, Bont LJ, Hoepelman AIM, Coenjaerts FEJ. High epidemic burden of RSV disease coinciding with genetic alterations causing amino acid substitutions in the RSV G-protein during the 2016/2017 season in The Netherlands. J Clin Virol. 2019;112:20–26. https://doi.org/10.1016/j.jcv.2019.01.007; König P, Giesow K, Schuldt K, Buchholz UJ, Keil GM. A novel protein expression strategy using recombinant bovine respiratory syncytial virus (BRSV): modifications of the peptide sequence between the two furin cleavage sites of the BRSV fusion protein yield secreted proteins, but affect processing and function of the BRSV fusion protein. J Gen Virol. 2004;85(Pt 7):1815–24. https://doi.org/10.1099/vir.0.80010-0; Yusuf S, Piedimonte G, Auais A, Demmler G, Krishnan S, Van Caeseele P, et al. The relationship of meteorological conditions to the epidemic activity of respiratory syncytial virus. Epidemiol Infect. 2007;135(7):1077–90. https://doi.org/10.1017/S095026880600776X; Hansen CL, Chaves SS, Demont C, Viboud C. Mortality associated with influenza and respiratory syncytial virus in the US, 1999–2018. JAMA Netw Open. 2022;5(2):e220527. https://doi.org/10.1001/jamanetworkopen.2022.0527; Johnstone J, Majumdar SR, Fox JD, Marrie TJ. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest. 2008;134(6):1141–8. https://doi.org/10.1378/chest.08-0888; Львов ДК, Бурцева ЕИ, Колобухина ЛВ, Федякина ИТ, Бовин НВ, Игнатьева АВ и др. Особенности циркуляции вирусов гриппа и ОРВИ в эпидемическом сезоне 2019– 2020 гг. в отдельных регионах России. Вопросы вирусологии. 2020;65(6):335–49. https://doi.org/10.36233/0507-4088-2020-65-6-4; Kim HW, Ganchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parroth RH. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89(4):422–34. https://doi.org/10.1093/oxfordjournals.aje.a120955; Johnson PR, Collins PL. The fusion glycoproteins of human respiratory syncytial virus of subgroups A and B: sequence conservation provides a structural basis for antigenic relatedness. J Gen Virol. 1988;69(Pt 10):2623–8. https://doi.org/10.1099/0022-1317-69-10-2623; Calder LJ, González-Reyes L, García-Barreno B, Wharton SA, Skehel JJ, Wiley DC, Melero JA. Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies. Virology. 2000;271(1):122–31. https://doi.org/10.1006/viro.2000.0279; Smith BJ, Lawrence MC, Colman PM. Modelling the structure of the fusion protein from human respiratory syncytial virus. Protein Eng. 2002;15(5):365–71. https://doi.org/10.1093/protein/15.5.365; McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013;340(6136):1113–7. https://doi.org/10.1126/science.1234914; McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013;342(6158):592–8. https://doi.org/10.1126/science.1243283; Crank MC, Ruckwardt TJ, Chen M, Morabito KM, Phung E, Costner PJ, et al. A proof of concept for structure-based vaccine design targeting RSV in humans. Science. 2019;365(6452):505–9. https://doi.org/10.1126/science.aav9033; Stephens LM, Varga SM. Considerations for a respiratory syncytial virus vaccine targeting an elderly population. Vaccines (Basel). 2021;9(6):624. https://doi.org/10.3390/vaccines9060624; Walsh EE, Falsey AR, Scott DA, Gurtman A, Zareba AM, Jansen KU, et al. A randomized phase 1/2 study of a respiratory syncytial virus prefusion F vaccine. J Infect Dis. 2022;225(8):1357–66. https://doi.org/10.1093/infdis/jiab612; Leroux-Roels I, Davis MG, Steenackers K, Essink B, Vandermeulen C, Fogarty C, et al. Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults: phase 1/2 randomized clinical trial. J Infect Dis. 2023;227(6):761–72. https://doi.org/10.1093/infdis/jiac327; Ferguson M, Murray A, Pliamm L, Rombo L, Sanmartin Berglund J, David MP, et al. Lot-to-lot immunogenicity consistency of the respiratory syncytial virus prefusion F protein vaccine in older adults. Vaccine X. 2024;18:100494. https://doi.org/10.1016/j.jvacx.2024.100494; Schmoele-Thoma B, Zareba AM, Jiang Q, Maddur MS, Danaf R, Mann A, et al. Vaccine efficacy in adults in a respiratory syncytial virus challenge study. N Engl J Med. 2022;386(25):2377–86. https://doi.org/10.1056/nejmoa2116154; Athan E, Baber J, Quan K, Scott RJ, Jaques A, Jiang Q, et al. Safety and immunogenicity of bivalent RSVpreF vaccine coadministered with seasonal inactivated influenza vaccine in older adults. Clin Infect Dis. 2024;78(5):1360–8. https://doi.org/10.1093/cid/ciad707; Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451–64. https://doi.org/10.1056/nejmoa2216480; Baker J, Aliabadi N, Munjal I, Jiang Q, Feng Y, Brock LG, et al. Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18–49 years of age: Results of a randomized phase 3 study. Vaccine. 2024;42(13):3172–9. https://doi.org/10.1016/j.vaccine.2024.03.070; Васин АВ, Егоров АЮ, Сергеева МВ, Стукова МА. Рекомбинантные векторные конструкции на основе аттенуированного вируса гриппа для разработки вакцин против респираторных инфекций. В кн.: III объединенный научный форум физиологов, биохимиков и молекулярных биологов. VII съезд биохимиков России. X Российский симпозиум «Белки и пептиды». VII съезд физиологов СНГ. Т. 2. Москва: Перо; 2021. С. 229–30. EDN: SXYWDM; Wilson E, Goswami J, Baqui AH, Doreski PA, PerezMarc G, Zaman K, et al. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N Engl J Med. 2023;389(24):2233–44. https://doi.org/10.1056/nejmoa2307079; Karron RA, Luongo C, Mateo JS, Wanionek K, Collins PL, Buchholz UJ. Safety and immunogenicity of the respiratory syncytial virus vaccine RSV/ΔNS2/Δ1313/ I1314L in RSV-seronegative children. J Infect Dis. 2020;222(1):82–91. https://doi.org/10.1093/infdis/jiz408; https://www.biopreparations.ru/jour/article/view/592

  4. 4
  5. 5
  6. 6
    Academic Journal

    Source: Сборник статей

    File Description: application/pdf

    Relation: Актуальные вопросы современной медицинской науки и здравоохранения: материалы VII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 17-18 мая 2022 г.; http://elib.usma.ru/handle/usma/9079

  7. 7
    Academic Journal

    Source: CHILDREN INFECTIONS; Том 21, № 2 (2022); 5-10 ; ДЕТСКИЕ ИНФЕКЦИИ; Том 21, № 2 (2022); 5-10 ; 2618-8139 ; 2072-8107 ; 10.22627/2072-8107-2022-21-2

    File Description: application/pdf

    Relation: https://detinf.elpub.ru/jour/article/view/721/554; О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2020 году: Государственный доклад. М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2021 г.:256.; Freymuth F, Vabret A, Dina J, Cuvillon-Nimal D, Lubin C, Vaudecrane A, Guillois B, Gouarin S, Petitjean J, Lafaix-Delaire F, Brouard J. Bronchiolitis viruses. Arch. Pediatr. 2010 Aug;17(8):1192—201. doi:10.1016/j.arcped.2010.05.006.; Midulla F, Scagnolari C, Bonci E, Pierangeli A, Antonelli G, De Angelis D, Berardi R, Moretti C. Respiratory syncytial virus, human bocavirus and rhinovirus bronchiolitis in infants. Arch. Dis. Child. 2010 Jan;9 5(1):35—41. doi:10.1136/adc.2008.153361.; Wong-Chew RM, Garcia-Leon ML, Noyola DE, Perez Gonzalez LF, Gaitan Meza J, Vilasenor-Sierra A, Martinez-Aguilar G, Rivera-Nunez VH, Newton-Sanchez OA, Firo-Reyes V, Del Rio-Almendarez CN, Gonzalez-Rodriguez AP, Ortiz-Garcia ER, Navarrete-Navarro S, Soria-Rodriguez C, Carrasco-Castillo A, Sanchez-Medina E, Lopez-Martinez I, Hernandez-Andrade T, Alpuche-Aranda CM, Santos-Preciado JI. Respiratory viruses detected in Mexican children younger than 5 years old with community-acquired pneumonia: a national multicenter study. Int. J Infect. Dis. 2017 Sep; 62:32—38. doi:10.1016/j.ijid.2017.06.020.; Скачкова М.А., Попкова Н.И., Карпова Е.Г., Тарасенко Н.Ф., Корнеев В.Г., Харченко О.А. Заболеваемость и смертность детей с пневмонией в Оренбургской области. Оренбургский медицинский вестник. 2016; IV, 1(13):47—51.; Naz R, Gul A, Javed U, Urooj A, Amin S, Fatima Z. Etiology of acute viral respiratory infections common in Pakistan: a review. Rev. Med. Virol. 2019 Mar; 29(2):e2024. doi:10.1002/rmv.2024.; Yen CY, Wu WT, Chang CY, Wong YC, Lai CC, Chan YJ, Wu KG, Hung MC. Viral etiologies of acute respiratory tract infections among hospitalized children — a comparison between single and multiple viral infections. J Microbiol. Immunol. Infect. 2019 Dec; 52(6):902—910. doi:10.1016/j.jmii.2019.08.013.; Piedimonte G, Perez MK. Respiratory syncytial virus infection and bronchiolitis. Pediatr. Rev. 2014 Dec; 35(12):519—30. doi:10.1542/pir.35-12-519.; Приказ Минздрава РФ от 27.05.97 № 170 (ред. от 12.01.98) «О переходе органов и учреждений здравоохранения Российской Федерации на Международную статистическую классификацию болезней и проблем, связанных со здоровьем X пересмотра».; Korsun N, Angelova S, Trifonova I, Georgieva I, Voleva S, Tzotcheva I, Mileva S, Ivanov I, Tcherveniakova T, Perenovska P. Viral pathogens associated with acute lower respiratory tract infections in children younger than 5 years of age in Bulgaria. Braz. J Microbiol. 2019 Jan; 50(1):117—125. doi:10.1007/s42770-018-0033-2.; Shi T, McAllister DA, O'Brien KL et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet, 2017; 390: 946—58. http://dx.doi.org/10.1016/S0140-6736(17)30938-8.; Horton KC, Dueger EL, Kandeel A, Abdallat M, El-Kholy A, Al-Awaidy S, Kohlani AH, Amer H, El-Khal AL, Said M, House B, Pimentel G, Talaat M. Viral etiology, seasonality and severity of hospitalized patients with severe acute respiratory infections in the Eastern Mediterranean Region, 2007—2014. PLoS One, 2017; 12 (7):e0180954. https://doi.org/10.1371/journal.pone.0180954.; Manning A, Russell V, Eastick K, Leadbetter GH, Hallam N, Templeton K, Simmonds P. Epidemiological profile and clinical associations of human bocavirus and other human parvoviruses. J Infect. Dis, 2006; 194(9):1283—90. https://doi.org/10.1086/508219.; Becerra M, Fiestas V, Tantaleán J, Mallma G, Alvarado M, Gutiérrez V, Huaringa M, Rojas N. Etiología viral de las infecciones respiratorias agudas graves en una unidad de cuidados intensivos pediátricos. Rev. perú. med. exp. salud publica, 2019; 36(2). Lima jun./set. http://dx.doi.org/10.17843/rpmesp.2019.362.4081.; Денисова А.Р., Максимов М.Л. Острые респираторные вирусные инфекции: этиология, диагностика, современный взгляд на лечение. РМЖ. 2018. «Медицинское обозрение»; 1(II):99—103.; Tregoning JS, Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev. 2010; 23(1):74—98. doi:10.1128/CMR.00032-09.; Galvаn JM, Rajas О, Aspa J. Revisiоn sobre las infecciones no bacterianas del aparato respiratorio: neumonias viricas. Arch. Bronconeumol. 2015; 51(11):590—597. DOI:10.1016/j.arbres.2015.02.015.; Алексеева Л.А., Бабаченко И.В., Григорьев С.Г., Бессонова Т.В., Макаренкова Е.В., Евдокимов К.В., Шарипова Е.В. Лабораторные критерии прогноза течения острых респираторных инфекций у детей. Медицинская технология. 2017:32—40.; https://detinf.elpub.ru/jour/article/view/721

  8. 8
  9. 9
    Academic Journal

    Source: Epidemiology and Vaccinal Prevention; Том 20, № 4 (2021); 28-39 ; Эпидемиология и Вакцинопрофилактика; Том 20, № 4 (2021); 28-39 ; 2619-0494 ; 2073-3046

    File Description: application/pdf

    Relation: https://www.epidemvac.ru/jour/article/view/1315/776; WHO Director-General’s opening remarks at the media briefing on COVID-19 — 11 March 2020. Доступно на: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19–11-march-2020. Ссылка активна на 01 апреля 2021.; WHO/Europe, 12 March 2021 Statement - COVID-19: a continued call for international solidarity and equity, 28th Standing Committee of the Regional Committee (SCRC), Third Session (virtual, 10–11 March 2021). Доступно на: https://www.euro.who.int/en/about-us/governance/standing-committee/twenty-eighth-standing-committeeof-the-regional-committee-for-europe-20202021/statement-covid-19-a-continued-call-for-international-solidarity-and-equity. Ссылка активна на 01 апреля 2021.; Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia. // Lancet. 2021. 397. P. 671–681.; Yang S, Li Y, Dai L, Wang J, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials // Lancet Infect Dis. 2021. Mar 24:S1473–3099(21)00127–4.; Thompson M., Burgess J., Naleway A., et.al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021 // MMWR. Early Release. 2021. Vol. 70. №13.P. 495–500.; Яковлев А. А., Раков А. В., Поздеева Е. С. Значение межвидовых и внутривидовых взаимодействий микроорганизмов как суборганизменного уровня в иерархии эпидемического процесса // Эпидемиология и инфекционные болезни. 2020. Т. 25, №3. C. 118–130.; World Health Organization. Interpreting influenza surveillance data in the context of the COVID-19 pandemic //Weekly epidemiological record. 2020. 95, №35. P. 409–416.; McCauley J., Daniels R., Harvey R., et.al. Report prepared for the WHO annual consultation on the composition of influenza vaccine for the Northern Hemisphere 2021-2022 // WIC, WHO CC for Reference & Research on Influenza. Доступно на: https://www.crick.ac.uk/partnerships/worldwide-influenza-centre/annual-and-interim-reports. Ссылка активна на 01 апреля 2021.; «О совершенствовании системы эпидемиологического надзора и контроля за гриппом и острыми респираторными вирусными инфекциями». Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека. Приказ №373 от 31.03.2005г.; Chadka M., Hirve S., Bancej C., et al. Human respiratory syncytial virus and influenza seasonality patterns – Early findings from the WHO global respiratory syncytial virus surveillance. // Influenza Other Respi Viruses. 2020.P.1–9.; Коншина О. С., Соминина А. А., Смородинцева Е. А. и др. Результаты многолетнего изучения популяционного иммунитета к вирусам гриппа A(H1N1)pdm09, A(H3N2) и В у взрослого населения России. // Инфекция и иммунитет. 2017. Т.7, №1. C.27–33.; Wu A, Mihaylova VT, Foxman EF. Interference between rhinovirus and influenza A virus: a clinical data analysis and experimental infection study. Lancet Microbe. 2020; № 1:254–262.; Gomez GB, Mahé C, Chaves SS. Uncertain effects of the pandemic on respiratory viruses. Science. 2021:Vol. 372, Issue 6546. P. 1043–1044.; Харченко Е. П. Вакцины против Сovid-19: сравнения, ограничения, спад пандемии и перспектива ОРВИ. Эпидемиология и Вакцинопрофилактика. 2020;20(1):.4–19.; Карпова Л. С., Лиознов Д. А., Столяров К. А. и др. COVID-19 в России. Весенне-летний период пандемии 2020 года. Эпидемиология и Вакцинопрофилактика. 2020;19(6):. 8–17.; COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Доступно на: https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6. Ссылка активна на 01 апреля 2021.; World Health Organization. Global influenza strategy 2019–2030. 2019. Доступно на: https://apps.who.int/iris/bitstream/handle/10665/311184/9789241515320-eng.pdf?ua=1. Ссылка активна на 01 апреля 2021.; https://www.epidemvac.ru/jour/article/view/1315

  10. 10
    Academic Journal

    Source: Meditsinskiy sovet = Medical Council; № 16 (2020); 95-100 ; Медицинский Совет; № 16 (2020); 95-100 ; 2658-5790 ; 2079-701X

    File Description: application/pdf

    Relation: https://www.med-sovet.pro/jour/article/view/5850/5336; Карнеева О.В., Поляков Д.П., Гуров А.В., Рязанцев С.В., Максимова Е.А., Казанова А.В. Острый средний отит. Клинические рекомендации Национальной медицинской ассоциации оториноларингологов. КР314. 2016. Режим доступа: http://glav-otolar.ru/assets/images/docs/clinicalrecomendations/KR314%20Ostryj%20srednij%20otit.pdf.; Chonmaitree T., Revai K., Grady J.J., Clos A., Patel J.A., Nair S., Fan J., Henrickson K.J.Viral upper respiratory tract infection and otitis media complication in young children. Clin Infect Dis. 2008;46(6):815–823. doi:10.1086/528685.; Kalu S.U., Ataya R.S., McCormick D.P., Patel J.A., Revai K., Chonmaitree T. Clinical spectrum of acute otitis media complicating upper respiratory tract viral infection. Pediatr Infect Dis J. 2011;30(2):95–99. doi:10.1097/INF.0b013e3181f253d5.; Buchman C.A., Brinson G.M. Viral Otitis Media. Current Allergy and Asthma Reports. 2003;3:335–340. doi:10.1007/s11882-003-0094-6.; Chonmaitree T., Trujillo R., Jennings K., Alvarez-Fernandez P., Patel J.A., Loeffelholz M.J. et al. Acute Otitis Media and Other Complications of Viral Respiratory. Infection Pediatrics. 2016;137(4):e20153555. doi:10.1542/peds.2015-3555.; Meriluoto M., Hedman L., Tanner L., Simell V., Mäkinen M., Simell S. et al. Association of human bocavirus 1 infection with respiratory disease in childhood follow-up study, Finland. Emerg Infect Dis. 2012;18(2):264–271. doi:10.3201/eid1802.111293.; Nokso-Koivisto J., Pyles R.B., Miller A.L., Patel J.A., Loeffelholz M., Chonmaitree T. Viral load and acute otitis media development after human metapneumovirus upper respiratory tract infection. Pediatr Infect Dis J. 2012;31(7):763–766. doi:10.1097/INF.0b013e3182539d92.; Verhoeven D., Xu Q., Pichichero M.E. Differential impact of respiratory syncytial virus and parainfluenza virus on the frequency of acute otitis media is explained by lower adaptive and innate immune responses in otitis-prone children. Clin Infect Dis. 2014;59(3):376–383. doi:10.1093/cid/ciu303.; Ruohola A., Pettigrew M.M., Lindholm L., Jalava J., Räisänen K.S., Vainionpää R. et al. Bacterial and viral interactions within the nasopharynx contribute to the risk of acute otitis media. J Infect. 2013;66(3):247– 254. doi:10.1016/j.jinf.2012.12.002.; Pettigrew M.M., Gent J.F., Pyles R.B., Miller A.L., Nokso-Koivisto J., Chonmaitree T. Viral-bacterial interactions and risk of acute otitis media complicating upper respiratory tract infection. J Clin Microbiol. 2011;49(11):3750–3755. doi:10.1128/JCM.01186-11.; Ruohola A., Meurman O., Nikkari S., Skottman T., Salmi A., Waris M. et al. Microbiology of acute otitis media in children with tympanostomy tubes: prevalences of bacteria and viruses. Clin Infect Dis. 2006;43(11):1417– 1422. doi:10.1086/509332.; Revai K., Dobbs L.A., Nair S., Patel J.A., Grady J.J., Chonmaitree T. Incidence of acute otitis media and sinusitis complicating upper respiratory tract infection: the effect of age. Pediatrics. 2007;119(6):e1408–e1412. doi:10.1542/peds.2006-2881.; Wiertsema S.P., Chidlow G.R., Kirkham L.A., Corscadden K.J., Mowe E.N., Vijayasekaran S. et al. High detection rates of nucleic acids of a wide range of respiratory viruses in the nasopharynx and the middle ear of children with a history of recurrent acute otitis media. J Med Virol. 2011;83(11):2008–2017. doi:10.1002/jmv.22221.; Heikkinen T., Thing M., Chonmaitree T. Prevalence of various respiratory viruses in the middle ear during acute otitis media. N Engl J Med. 1999;340(4):260–264. doi:10.1056/NEJM199901283400402.; Rosenfeld R.M., Shin J.J., Schwartz S.R., Coggins R., Gagnon L., Hackell J.M. et al. Clinical Practice Guideline: Otitis Media with Effusion (Update). Otolaryngol Head Neck Surg. 2016;154(1 Suppl):1–41. doi:10.1177/0194599815623467; Lieberthal A.S., Carroll A.E., Chonmaitree T., Ganiats T.G., Hoberman A., Jackson M.A. et al. The Diagnosis and Management of Acute Otitis Media. Pediatrics. 2013;131(3):e964–e999. doi:10.1542/peds.2012-3488.; Patel J.A., Nair S., Revai K., Grady J., Saeed K., Matalon R., Block S., Chonmaitree T. Association of proinflammatory cytokine gene polymorphisms with susceptibility to otitis media. Pediatrics. 2006;118(6):2273– 2279. doi:10.1542/peds.2006-0764.; Revai K., Patel J.A., Grady J.J., Nair S., Matalon R., Chonmaitree T. Association between cytokine gene polymorphisms and risk for upper respiratory tract infection and acute otitis media. Clin Infect Dis. 2009;15;49(2):257–261. doi:10.1086/599833.; Alper C.M., Winther B., Hendley J.O., Doyle W.J. Cytokine polymorphisms predict the frequency of otitis media as a complication of rhinovirus and RSV infections in children. Eur Arch Otorhinolaryngol. 2009;266(2):199– 205. doi:10.1007/s00405-008-0729-2.; Emonts M., Veenhoven R.H., Wiertsema S.P., Houwing-Duistermaat J.J., Walraven V., de Groot R., Hermans P.W., Sanders E.A. Genetic polymorphisms in immunoresponse genes TNFA, IL6, IL10, and TLR4 are associated with recurrent acute otitis media. Pediatrics. 2007;120(4):814–823. doi:10.1542/peds.2007-0524.; Norhayati M.N., Ho J.J., Azman M.Y. Influenza vaccines for preventing acute otitis media in infants and children. Cochrane Database Syst Rev. 2015;(3):CD010089. doi:10.1002/14651858.CD010089.; Heikkinen T., Block S.L., Toback S.L., Wu X., Ambrose C.S. The efficacy of live attenuated influenza vaccine against influenza-associated acute otitis media in children. Pediatr Infect Dis J. 2013;32(6):669–674. doi:10.1097/INF.0b013e3181faac7c.; Nokso-Koivisto J.P.R., Miller A., Jennings K., Loeffelholz M.J., Chonmaitree T. Role of Human Bocavirus in Upper Respiratory Tract Infections and Acute Otitis Media. J Pediatric Infect Dis Soc. 2014;3(2):98–103. doi:10.1093/jpids/pit061.; Grijalva C.G., Nuorti J.P., Griffin M.R. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA. 2009;302(7):758–766. doi:10.1001/jama.2009.1163.; Пальчун В.Т. Оториноларингология: национальное руководство. М.: ГЭОТАР-Медиа; 2009. 960 с.; Ищенко Н.В., Сергиенко А.В. Отипакс в клинической практике. Международный журнал экспериментального образования. 2016;(9-2):333. Режим доступа: http://www.expeducation.ru/ru/article/view?id=10523.; Marom T., Tan A., Wilkinson G.S., Pierson K.S., Freeman J.L., Chonmaitree T. Trends in otitis media-related healthcare use in the United States, 2001–2011. JAMA Pediatr. 2014;168(1):68–75. doi:10.1001/jamapediatrics.2013.3924.; Yin J.K., Salkeld G., Lambert S.B., Dierig А., Heron L., Leask J. et al. Estimates and determinants of economic impacts from influenza-like illnesses caused by respiratory viruses in Australian children attending childcare: a cohort study. Influenza Other Respir Viruses. 2013;7(6):1103– 1112. doi:10.1111/irv.12138.; Ede L.C., Loeffelholz M.J., Alvarez-Fernandez P., Pong D.L., Patel J.A., McCormick D.P., Chonmaitree T. Effect of the 2009 influenza A/H1N1 pandemic on viral respiratory infections in the first year of life. Pediatr Infect Dis J. 2012;31(11):1107–1112. doi:10.1097/INF.0b013e31825f29db.; Stockmann C., Ampofo K., Hersh A.L., Carleton S.T., Korgenski K., Sheng X., et al. Seasonality of acute otitis media and the role of respiratory viral activity in children. Pediatr Infect Dis J. 2013;32(4):314–319. doi:10.1097/INF.0b013e31827d104e.; Chonmaitree T., Alvarez-Fernandez P., Jennings K., Trujillo R., Marom T., Loeffelholz M.J. et al. Symptomatic and asymptomatic respiratory viral infections in the first year of life: association with acute otitis media. Clin Infect Dis. 2015;60(1):1–9. doi:10.1093/cid/ciu714.

  11. 11
    Academic Journal

    Source: CHILDREN INFECTIONS; Том 17, № 2 (2018); 21-28 ; ДЕТСКИЕ ИНФЕКЦИИ; Том 17, № 2 (2018); 21-28 ; 2618-8139 ; 2072-8107 ; 10.22627/2072-8107-2018-17-2

    File Description: application/pdf

    Relation: https://detinf.elpub.ru/jour/article/view/360/340; Заплатников А.Л., Короид Н.В., Гирина А.А., Мукашева Е.А., Бурцева Е.И. Лечение гриппа и других острых респираторных вирусных инфекций у детей. Вопросы практической педиатрии. 2013; 8(5):51—57.; Кокорева С.П., Трушкина А.В., Разуваев О.А. Оптимизация этиотропной терапии острых респираторных вирусных инфекций у детей. Детские инфекции. 2013; 12(4):42—46. https://doi.org/10.22627/2072-8107-2013-12-4-42-46; Малиновская В.В., Тимина В.П., Мазанкова Л.Н., Чеботарева Т.А. Иммунопатогенез острых респираторных инфекций, тактика рационального выбора этиотропной и иммуномодулирующей терапии у детей. Детские инфекции. 2013; 12(4):14—19. https://doi.org/10.22627/2072-8107-2013-12-4-14-19; Михайлова Е.В., Чудакова Т.К., Данилов А.Н. Клинические особенности острых респираторных вирусных инфекций и совершенствование терапии в группе часто болеющих детей. Эпидемиология и инфекционные болезни. 2014; 3:58—62.; Резолюция совещания экспертов по вопросам профилактики острых респираторных заболеваний у детей в возрасте до 2 лет. Детские инфекции. 2012;11(1):5.; Сенцова Т.Б., Ревякина В.А., Ворожко И.В., Кириллова О.О., Моносова О.Ю. Современные аспекты применения иммуномодуляторов в лечении и профилактике респираторных вирусных инфекций у детей. Вопросы практической педиатрии. 2011; 6(5):100—103.; Файзулоев Е.Б., Лободанов С.А., Никонова А.А., Каира А.Н., Полухина Г.М., Трушакова С.В., Шевченко Е.С и соавт. Дифференциальная диагностика ОРВИ методом мультиплексной ПЦР с детекцией в режиме реального времени. Эпидемиология и вакцинопрофилактика. 2012; 1(62):12—18.; Marie-Therese Labro. Immunomodulatory effects of antimicrobial agents. Part I: antibacterial and antiviral agents. Expert Review of Anti-infective Therapy. 2012; 10(3):319—340.; Шарашкина Н.В., Никитина И.В., Бурменская О.В., Непша О.С., Донников А.Е, Трофимов Д.Ю., Рунихина Н.К., Ионов О.В., Кан Н.Е., Тютюнник В.Л. Анализ результатов использования метода полимеразной цепной реакции в режиме реального времени для диагностики острых респираторных заболеваний и гриппа у беременных женщин и новорожденных в период эпидемий. Акушерство и гинекология. 2014; 6: 66—73.; Sappenfield E., Jamieson D.J., Kourtis A.P. Pregnancy and susceptibility to infectious diseases. Infect. Dis. Obstet. Gynecol. 2013; 2013: 752852.; Lanari M et al. The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infection. Clinical and Developmental Immunology. 2013; 1—9.; Чеботарева Т.А., Заплатников А.Л., Захарова И.Н., Выжлова Е.Н. Современные возможности интерферонотерапии при гриппе и острых респираторных инфекциях у детей. Детские инфекции. 2013. 12(2):35—38. https://doi.org/10.22627/2072-8107-2013-12-2-35-38]; Львов Н.И., Жданов К.В., Гришин И.С., Мальцев О.В., Жабров С.С., Голованова А.К и др. Этиология аденовирусных заболеваний в организованных коллективах. Инфекционные болезни. 2012; 10 (Прил.1):228.; Шипицын К.С., Огарков П.И., Смиронов В.С., Жоголев С.Д., Жоголев К.Д. Профилактика острых респираторных вирусных инфекций и пневмоний в организованном коллективе. Эпидемиология и инфекционные болезни. 2010; 1:57—61.; Ревякина В.А. Перспективы использования растительных иммуномодуляторов в профилактике и терапии респираторных инфекций у детей. Инфекционные болезни. 2013;11(1):93—96.; https://detinf.elpub.ru/jour/article/view/360

  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
    Academic Journal

    Source: Current Pediatrics; Том 11, № 4 (2012); 142-147 ; Вопросы современной педиатрии; Том 11, № 4 (2012); 142-147 ; 1682-5535 ; 1682-5527

    File Description: application/pdf

    Relation: https://vsp.spr-journal.ru/jour/article/view/469/374; Joffe S., Escobar G. J., Black S. B. et al. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics. 1999; 104: 894–899.; Lacaze-Masmonteil T., Truffert P., Pinquier D. et al. Lower respiratory tract illness and RSV prophylaxis in very premature infants. Arch. Dis. Child. 2004; 89: 562–567.; Shay D. K., Holman R. C., Newman R. D. et al. Bronchiolitisassociated hospitalizations among US children, 1980–1996. JAMA. 1999; 282: 1440–1446.; Hampp С., Saidi A., Winterstein A. Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida. J. Pediatr. 2010; 156 (6): 953–959.; Checchia P., Nalysnyk L., Fernandes A. et al. Mortality and morbidity among high-risk preterm infants receiving palivizumab prophylaxis: a systematic review and meta-analysis. Pediatr. Crit. Care Med. 2011; 12 (5): 580–588.; American Academy of Pediatrics. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in highrisk infants (The IMpact-RSV Study Group). Pediatrics. 1998; 102: 531–537.; Kusuda S. et al. Results of clinical surveillance during the Japanese first palivizumab season in 2002–2003. Pediatr. Int. 2006; 48: 362–368.; Perez Perez G., Navarro Merino M. Perez R. et al. Respiratory morbidity after hospital discharge in premature infants born at < or = 32 weeks gestation with bronchopulmonary dysplasia. Anales de Pediatria. 2004; 60: 117–124.; Shrier I., Boivin J.-F., Steele R. et al. Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles. Am. J. Epidemiol. 2007; 166: 1203–1209.; Garrison L., Neumann P., Erickson P. et al. Using real-world data for coverage and payment decisions: the ISPOR Real- World Data Task Force report. Value Health. 2007; 10 (5): 326–335.; Life tables for WHO Member States. 2009. (www.who.int); Henderson J., Hilliard T. N., Sherriff A. et al. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: A longitudinal birth cohort study. Pediatr. Allergy Immunol. 2005; 16: 386–392.; Дрожжев М. Е. и др. Современные показатели распространенности бронхиальной астмы среди детей. Пульмонология. 2002; 1: 42–46.; Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». 3-е изд., испр. и доп. М.: Атмосфера. 2008. 108.; Артюхов И. П., Ильенкова Н. А., Шульмин А. В., Степанова Л. В. Анализ клинико-экономической эффективности регулярного наблюдения врачом-аллергологом детей с бронхиальной астмой. Сибирский медицинский журнал. 2010; 5: 100–102.; Приложения к Генеральному тарифному соглашению по тарифам на медицинскую помощь (медицинские услуги) и условиям оплаты медицинской помощи, оказываемой в рамках действующей Территориальной программы обязательного медицинского страхования граждан Российской Федерации в Санкт-Петербурге на 2012 г. (www.spboms.ru); Зырянов С. К., Белоусов Ю. Б. Фармакоэкономическая оценка терапии бронхиальной астмы Форадилом Комби. Фарма коэкономика. 2011; 4 (4): 41–49.; Доскин В. А., Келлер Х., Мураенко Н. М., Тонкова-Ямпольская Р. В. Морфофункциональные константы детского организма: справочник. М.: Медицина. 1997. 288 с.; Дементьева Г. М., Короткова Е. В. Дифференцированная оцен ка детей с низкой массой при рождении. Вопр. охр. мат. и дет. 1981; 2: 15–20.; Chiou C. F., Weaver M. R. et al. Development of the multiattribute Pediatric Asthma Health Outcome Measure (PAHOM). Int. J. Qual. Health Care. 2005; 17: 23–30.; Hlatky M., Owens D., Sanders G. Cost-effectiveness as an outcome in randomized clinical trials. Clin. Trial.s 2006; 3: 543. DOI:10.1177/1740774506073105.; Rawlins M., Culyer A. National Institute for Clinical Excellence and its value judgments. BMJ. 2004; 329: 224–227.; Resch В., Gusenleitnerl W., Nuijten M. et al. Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria. Clin. Therapeutics. 2008; 30 (4): 749–760.; World Health Organization. Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Geneva (Switzerland): World Health Organization. 2001.; Gaziano T. Cardiovascular disease in the developing world and its costeffective management. Cardiology Rounds. 2005; 9 (2): 3547–3553.

  19. 19
  20. 20